中华老年医学杂志
中華老年醫學雜誌
중화노년의학잡지
Chinese Journal of Geriatrics
2010年
5期
370-373
,共4页
吴彧%王丽霞%韩跃刚%卢建敏
吳彧%王麗霞%韓躍剛%盧建敏
오욱%왕려하%한약강%로건민
血脂康%颈动脉粥样硬化%内皮素-1%一氧化氮%谷胱甘肽
血脂康%頸動脈粥樣硬化%內皮素-1%一氧化氮%穀胱甘肽
혈지강%경동맥죽양경화%내피소-1%일양화담%곡광감태
Xuezhikang%Carotid atherosclerosis%Nitric oxide%Endothelin-1%Glutathione
目的 探讨血脂康对颈动脉粥样硬化患者调脂作用及对血管内皮功能和血浆氧化还原平衡的影响.方法 选择来我院心内科住院的颈动脉粥样硬化患者108例,随机分为血脂康组(54例)和考来烯胺组(54例),分别测定两组患者治疗12周前后总胆固醇(TC)、三酰甘油(TG)、低密度脂蛋白胆固醇(LDL-C)、一氧化氮(NO)、内皮素-1(ET-1)、还原型谷胱甘肽(GSH)和氧化型谷胱甘肽(GSSG),并根据Nernst方程计算GSH/GSSG氧化还原电位.结果 治疗12周后,TC、LDL-C和TG血脂康组从治疗前的(5.68±1.47、3.43±1.36、1.73±0.6 6)mmol/L降低到治疗后的(3.94±1.36、2.28±1.11、1.54±0.59)mmol/L(t值分别为3.915、4.160、2.187,P值分别为<0.01、0.01、0.05),考来烯胺组(5.73±1.52、3.37±1.35、1.72±0.67)mmol/L降低到治疗后的(4.15±1.29、2.56±1.06、1.69±0.57)mmol/L(t值分别为3.760、4.035、1.893,P值分别为<0.01、0.01、>0.05);血脂康组ET-1、GSSG、GSSG/GSH从[(154.43±63.06)ng/L、(33.93±1.74)μmol/L、-142.3±4.3]降低到[(121.71±59.11)ng/L、(30.42±1.59)μmol/L、-146.1±4.4(t值分别为2.168、2.325、4.168,P值分别为<0.05、0.05、0.01)];NO、NO/ET-1、GSH、GSH/GSSG从(48.41±16.53)μmol/L、0.33±0.16、(286.11±38.23)μmol/L、8.65±1.18升高到(64.40±18.86)μmol/L、0.54±0.19、(321.27±56.47)μmol/L、10.56±1.70(t值分别为3.725、3.987、3.894、4.168,P值分别为<0.01、0.01、0.01、0.01).结论 对颈动脉粥样硬化患者,血脂康和考来烯胺均可有效调脂,但仅血脂康对血管内皮功能有一定的保护作用,且可使氧化还原平衡向还原方向偏移.
目的 探討血脂康對頸動脈粥樣硬化患者調脂作用及對血管內皮功能和血漿氧化還原平衡的影響.方法 選擇來我院心內科住院的頸動脈粥樣硬化患者108例,隨機分為血脂康組(54例)和攷來烯胺組(54例),分彆測定兩組患者治療12週前後總膽固醇(TC)、三酰甘油(TG)、低密度脂蛋白膽固醇(LDL-C)、一氧化氮(NO)、內皮素-1(ET-1)、還原型穀胱甘肽(GSH)和氧化型穀胱甘肽(GSSG),併根據Nernst方程計算GSH/GSSG氧化還原電位.結果 治療12週後,TC、LDL-C和TG血脂康組從治療前的(5.68±1.47、3.43±1.36、1.73±0.6 6)mmol/L降低到治療後的(3.94±1.36、2.28±1.11、1.54±0.59)mmol/L(t值分彆為3.915、4.160、2.187,P值分彆為<0.01、0.01、0.05),攷來烯胺組(5.73±1.52、3.37±1.35、1.72±0.67)mmol/L降低到治療後的(4.15±1.29、2.56±1.06、1.69±0.57)mmol/L(t值分彆為3.760、4.035、1.893,P值分彆為<0.01、0.01、>0.05);血脂康組ET-1、GSSG、GSSG/GSH從[(154.43±63.06)ng/L、(33.93±1.74)μmol/L、-142.3±4.3]降低到[(121.71±59.11)ng/L、(30.42±1.59)μmol/L、-146.1±4.4(t值分彆為2.168、2.325、4.168,P值分彆為<0.05、0.05、0.01)];NO、NO/ET-1、GSH、GSH/GSSG從(48.41±16.53)μmol/L、0.33±0.16、(286.11±38.23)μmol/L、8.65±1.18升高到(64.40±18.86)μmol/L、0.54±0.19、(321.27±56.47)μmol/L、10.56±1.70(t值分彆為3.725、3.987、3.894、4.168,P值分彆為<0.01、0.01、0.01、0.01).結論 對頸動脈粥樣硬化患者,血脂康和攷來烯胺均可有效調脂,但僅血脂康對血管內皮功能有一定的保護作用,且可使氧化還原平衡嚮還原方嚮偏移.
목적 탐토혈지강대경동맥죽양경화환자조지작용급대혈관내피공능화혈장양화환원평형적영향.방법 선택래아원심내과주원적경동맥죽양경화환자108례,수궤분위혈지강조(54례)화고래희알조(54례),분별측정량조환자치료12주전후총담고순(TC)、삼선감유(TG)、저밀도지단백담고순(LDL-C)、일양화담(NO)、내피소-1(ET-1)、환원형곡광감태(GSH)화양화형곡광감태(GSSG),병근거Nernst방정계산GSH/GSSG양화환원전위.결과 치료12주후,TC、LDL-C화TG혈지강조종치료전적(5.68±1.47、3.43±1.36、1.73±0.6 6)mmol/L강저도치료후적(3.94±1.36、2.28±1.11、1.54±0.59)mmol/L(t치분별위3.915、4.160、2.187,P치분별위<0.01、0.01、0.05),고래희알조(5.73±1.52、3.37±1.35、1.72±0.67)mmol/L강저도치료후적(4.15±1.29、2.56±1.06、1.69±0.57)mmol/L(t치분별위3.760、4.035、1.893,P치분별위<0.01、0.01、>0.05);혈지강조ET-1、GSSG、GSSG/GSH종[(154.43±63.06)ng/L、(33.93±1.74)μmol/L、-142.3±4.3]강저도[(121.71±59.11)ng/L、(30.42±1.59)μmol/L、-146.1±4.4(t치분별위2.168、2.325、4.168,P치분별위<0.05、0.05、0.01)];NO、NO/ET-1、GSH、GSH/GSSG종(48.41±16.53)μmol/L、0.33±0.16、(286.11±38.23)μmol/L、8.65±1.18승고도(64.40±18.86)μmol/L、0.54±0.19、(321.27±56.47)μmol/L、10.56±1.70(t치분별위3.725、3.987、3.894、4.168,P치분별위<0.01、0.01、0.01、0.01).결론 대경동맥죽양경화환자,혈지강화고래희알균가유효조지,단부혈지강대혈관내피공능유일정적보호작용,차가사양화환원평형향환원방향편이.
Objective To explore the effect of xuezhikang on blood lipids,vascular endothelial function and redox balance in patients with carotid atherosclerosis.Methods A total of 108 inpatients with carotid atherosclerosis in cardiology department were randomly divided into two groups:xuezhikang group (n = 54) and cholestyramin group (n= 54).Before and after treatment,the levels of total cholesterol (TC),triglyceride (TG),low density lipoprotein cholesterol (LDL-C),nitric oxide (NO),endothelin-1 (ET-1),reduced glutathione (GSH) and oxidized glutathione (GSSG) of all patients were measured.The GSH/GSSG as redox potentials were calculated according to Nernst equation.Results After 12 weeks of treatment,the levels of blood lipids were lower than before treatment in xuezhikang group [TC:(3.94±1.36) mmol/L vs.(5.68±1.47) mmol/L;LDL-C:(2.28±1.11) mmol/L vs.(3.43±1.36) mmol/L;TG:(1.54±0.59) mmol/L vs.(1.73±0.66)mmol/L;t=3.915,4.160,2.187;P<0.01,0.01,0.05,respectively],and the levels of blood lipids also decreased in cholestyramin group [TC:(4.15 ± 1.29) mmol/L vs.(5.73 ± 1.52)mmol/L;LDLC:(2.56± 1.06) mmol/L vs.(3.37± 1.35) mmol/L;TG:(1.69±0.57) mmol/L vs.(1.72±0.67) mmol/L;t=3.760,4.035,1.893;P<0.01,0.01,>0.05,respectively].In xuezhikang group,ET-1,GSSG and GSSG/GSH ratios decreased significantly [(121.71 + 59.11) ng/L vs.(154.43±63.06) ng/L;(30.42± 1.59) μmol/L vs.(33.93±1.74) μ mol/L;-146.1±4.4vs.-142.3±4.3;t=2.168,2.325,4.168;P<0.05,0.05,0.01,respectively],and NO,NO/ET-1 ratios,GSH and GSH/GSSG increased significantly [(64.40 ± 18.86) μmol/L vs.(48.41 ±16.53) μmol/L;(0.54±0.19) vs.(0.33±0.16);(321.27±56.47) μmol/L vs.(286.11±38.23)μmol/L;(10.56±1.70) vs.(8.65±1.18);t=3.725,3.987,3.894,4.168;all P<0.01].Conclusions For patients with carotid atherosclerosis,both xuezhikang and cholestyramin could lower blood lipids efficiently,but only xuezhikang could protect vascular endothelial function partly,and makes plasma redox imbalance shift the balance.
